Regeneus (ASX:RGS) - CEO, Karolis Rosickas
CEO, Karolis Rosickas
Source: LOGIN Conferences
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Clinical-stage regenerative medicine company Regeneus (RGS) has appointed Karolis Rosickas as CEO, following the resignation of Leo Lee
  • Karolis has over 15 years of experience in healthcare, technology and finance
  • Most recently, he was CEO and Co-Founder for a nutrition technology business, OME Health
  • The former CEO resigned to take on a new  role in a major Japanese pharmaceutical company, however, Leo will remain with Regeneus as a Non-Executive Director
  • Shares in Regeneus closed 7.41 per cent lower, at 12.5 cents

Regeneus (RGS), has appointed Karolis Rosickas as CEO, following the resignation of Leo Lee.

Karolis has more than 15 years’ experience across healthcare, technology and finance businesses.

Prior to his appointment, he was CEO and Co-Founder for a nutrition technology business, OME Health. He also co-founded SingCell, a stem cell contract development and manufacturing organisation.

Mr Rosickas had previously held senior positions with investment banking company HSBC, JP Morgan, KPMG and multinational food-products corporation, Danone.

He is a certified chartered financial analyst and with a Masters in Business Administration.

Regeneus Independent Chairman Barry Sechos said Karolis’ appointment would be a significant step for the company’s growth.

“His experience in the healthcare and finance sectors will be invaluable for the company, furthermore, his experience as a Co-Founder of an organisation dedicated to stem cell development and manufacturing will be critical for Regeneus’ next phase of growth,” he said.

“We thank Leo for his service and are delighted that the company will continue to benefit from his strategic guidance as a Non-Executive Director,” he added.

Meanwhile, Leo Lee has resigned as CEO of the company for a new role in a major Japanese pharmaceutical company. He’ll remain on the Regeneus board as a Non-Executive Director.  

Shares in Regeneus closed 7.41 per cent lower, at 12.5 cents. 

RGS by the numbers
More From The Market Online

Market shrugs as Fisher & Paykel announces mass recall

Fisher & Paykel has initiated a voluntary limited recall of batches of Airvo 1 and my…
The Market Online Video

Brian Leedman’s BlinkLab to join ASX: AI-driven smartphone app screens for autism, ADHD

BlinkLab is a world-first, AI-driven digital healthcare venture, that uses a smartphone and facial recognition to…

Osteopore stock spikes 900% on Singapore and Vietnam approvals

Osteopore's (ASX:OSX) share price was up 38% after the regenerative medicine company received approval for its…

Amplia Therapeutics takes step up in pancreatic cancer treatment

Amplia Therapeutics is on to next step in its pancreatic cancer treatment research after a successful…